|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PTTG1IP |
Gene summary for PTTG1IP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PTTG1IP | Gene ID | 754 |
| Gene name | PTTG1 interacting protein | |
| Gene Alias | C21orf1 | |
| Cytomap | 21q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | B4DPZ0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 754 | PTTG1IP | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.70e-11 | 3.40e-01 | 0.0155 |
| 754 | PTTG1IP | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.71e-17 | 1.11e+00 | -0.1808 |
| 754 | PTTG1IP | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.07e-12 | 8.12e-01 | -0.0811 |
| 754 | PTTG1IP | HTA11_78_2000001011 | Human | Colorectum | AD | 9.33e-07 | 5.33e-01 | -0.1088 |
| 754 | PTTG1IP | HTA11_347_2000001011 | Human | Colorectum | AD | 2.47e-42 | 1.18e+00 | -0.1954 |
| 754 | PTTG1IP | HTA11_411_2000001011 | Human | Colorectum | SER | 1.99e-10 | 2.12e+00 | -0.2602 |
| 754 | PTTG1IP | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.06e-07 | 1.24e+00 | -0.2196 |
| 754 | PTTG1IP | HTA11_83_2000001011 | Human | Colorectum | SER | 3.75e-08 | 7.48e-01 | -0.1526 |
| 754 | PTTG1IP | HTA11_696_2000001011 | Human | Colorectum | AD | 7.73e-21 | 6.78e-01 | -0.1464 |
| 754 | PTTG1IP | HTA11_866_2000001011 | Human | Colorectum | AD | 1.92e-05 | 3.82e-01 | -0.1001 |
| 754 | PTTG1IP | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.02e-12 | 8.25e-01 | -0.059 |
| 754 | PTTG1IP | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.11e-05 | 8.04e-01 | -0.1706 |
| 754 | PTTG1IP | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.25e-17 | 1.55e+00 | -0.2061 |
| 754 | PTTG1IP | HTA11_546_2000001011 | Human | Colorectum | AD | 1.20e-03 | 4.63e-01 | -0.0842 |
| 754 | PTTG1IP | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.15e-03 | 5.43e-01 | -0.0179 |
| 754 | PTTG1IP | HTA11_866_3004761011 | Human | Colorectum | AD | 2.14e-06 | 3.92e-01 | 0.096 |
| 754 | PTTG1IP | HTA11_4255_2000001011 | Human | Colorectum | SER | 2.95e-02 | 4.43e-01 | 0.0446 |
| 754 | PTTG1IP | HTA11_7663_2000001011 | Human | Colorectum | SER | 8.29e-03 | 3.94e-01 | 0.0131 |
| 754 | PTTG1IP | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.52e-04 | 3.30e-01 | 0.0674 |
| 754 | PTTG1IP | HTA11_7469_2000001011 | Human | Colorectum | AD | 1.21e-05 | 1.14e+00 | -0.0124 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00435161 | Liver | HCC | regulation of DNA damage response, signal transduction by p53 class mediator | 22/7958 | 34/18723 | 7.46e-03 | 2.96e-02 | 22 |
| GO:190225312 | Liver | HCC | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 19/7958 | 29/18723 | 1.05e-02 | 3.89e-02 | 19 |
| GO:007259418 | Oral cavity | OSCC | establishment of protein localization to organelle | 284/7305 | 422/18723 | 1.50e-32 | 1.35e-29 | 284 |
| GO:200123320 | Oral cavity | OSCC | regulation of apoptotic signaling pathway | 242/7305 | 356/18723 | 6.66e-29 | 3.24e-26 | 242 |
| GO:009719320 | Oral cavity | OSCC | intrinsic apoptotic signaling pathway | 202/7305 | 288/18723 | 4.64e-27 | 1.73e-24 | 202 |
| GO:000989620 | Oral cavity | OSCC | positive regulation of catabolic process | 307/7305 | 492/18723 | 2.29e-26 | 7.64e-24 | 307 |
| GO:003133120 | Oral cavity | OSCC | positive regulation of cellular catabolic process | 273/7305 | 427/18723 | 6.39e-26 | 2.02e-23 | 273 |
| GO:004217620 | Oral cavity | OSCC | regulation of protein catabolic process | 254/7305 | 391/18723 | 1.07e-25 | 3.22e-23 | 254 |
| GO:000691317 | Oral cavity | OSCC | nucleocytoplasmic transport | 204/7305 | 301/18723 | 2.65e-24 | 6.98e-22 | 204 |
| GO:005116917 | Oral cavity | OSCC | nuclear transport | 204/7305 | 301/18723 | 2.65e-24 | 6.98e-22 | 204 |
| GO:003450415 | Oral cavity | OSCC | protein localization to nucleus | 193/7305 | 290/18723 | 1.22e-21 | 2.35e-19 | 193 |
| GO:190336220 | Oral cavity | OSCC | regulation of cellular protein catabolic process | 174/7305 | 255/18723 | 2.04e-21 | 3.70e-19 | 174 |
| GO:200124220 | Oral cavity | OSCC | regulation of intrinsic apoptotic signaling pathway | 123/7305 | 164/18723 | 5.71e-21 | 9.77e-19 | 123 |
| GO:190332020 | Oral cavity | OSCC | regulation of protein modification by small protein conjugation or removal | 165/7305 | 242/18723 | 2.52e-20 | 3.99e-18 | 165 |
| GO:003139620 | Oral cavity | OSCC | regulation of protein ubiquitination | 143/7305 | 210/18723 | 1.01e-17 | 9.80e-16 | 143 |
| GO:200123420 | Oral cavity | OSCC | negative regulation of apoptotic signaling pathway | 148/7305 | 224/18723 | 1.71e-16 | 1.36e-14 | 148 |
| GO:004573220 | Oral cavity | OSCC | positive regulation of protein catabolic process | 150/7305 | 231/18723 | 1.06e-15 | 7.64e-14 | 150 |
| GO:001703815 | Oral cavity | OSCC | protein import | 136/7305 | 206/18723 | 3.15e-15 | 2.08e-13 | 136 |
| GO:190336420 | Oral cavity | OSCC | positive regulation of cellular protein catabolic process | 106/7305 | 155/18723 | 1.07e-13 | 5.53e-12 | 106 |
| GO:200124320 | Oral cavity | OSCC | negative regulation of intrinsic apoptotic signaling pathway | 73/7305 | 98/18723 | 9.33e-13 | 4.22e-11 | 73 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PTTG1IP | SNV | Missense_Mutation | novel | c.457N>A | p.Glu153Lys | p.E153K | P53801 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PTTG1IP | SNV | Missense_Mutation | c.124N>G | p.Gln42Glu | p.Q42E | P53801 | protein_coding | tolerated(1) | benign(0.003) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PTTG1IP | SNV | Missense_Mutation | rs138357182 | c.308N>T | p.Ser103Leu | p.S103L | P53801 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PTTG1IP | SNV | Missense_Mutation | rs758698293 | c.151N>C | p.Cys51Arg | p.C51R | P53801 | protein_coding | deleterious(0) | benign(0.332) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
| PTTG1IP | SNV | Missense_Mutation | rs374480622 | c.418N>T | p.Arg140Trp | p.R140W | P53801 | protein_coding | deleterious(0) | possibly_damaging(0.855) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PTTG1IP | SNV | Missense_Mutation | c.259N>T | p.Arg87Cys | p.R87C | P53801 | protein_coding | deleterious(0) | probably_damaging(0.917) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PTTG1IP | SNV | Missense_Mutation | rs778141805 | c.449G>A | p.Arg150Gln | p.R150Q | P53801 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PTTG1IP | SNV | Missense_Mutation | novel | c.466A>T | p.Thr156Ser | p.T156S | P53801 | protein_coding | tolerated(0.43) | benign(0.005) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PTTG1IP | SNV | Missense_Mutation | novel | c.130A>G | p.Thr44Ala | p.T44A | P53801 | protein_coding | deleterious(0.01) | benign(0.005) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PTTG1IP | SNV | Missense_Mutation | c.177N>C | p.Trp59Cys | p.W59C | P53801 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-69-7979-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |